Search Results - "Hatjiharissi, E"

Thromboembolic events in patients with paroxysmal nocturnal hemoglobinuria (PNH): Real world data of a Greek nationwide multicenter retrospective study by Chatzileontiadou, S, Hatjiharissi, E, Angelopoulou, M, Asimakopoulos, J V, Loutsidi, N E, Chatzikonstantinou, T, Zikos, P, Bouchla, A, Bezirgiannidou, Z, Kouvata, E, Frouzaki, C, Chaloudis, P, Sotiropoulos, D, Douka, V, Sirigou, A, Mandala, E, Psyllaki, M, Papadaki, H A, Marinakis, T, Viniou, N A, Kokkori, S, Kontopidou, F, Skepetari, A, Vassilopoulos, G, Kotsianidis, I, Pappa, V, Lalayanni, C, Baltadakis, I, Delimpassi, S, Pagoni, M, Papaioannou, M

“…Thrombosis is the most common and a life-threatening complication in patients with Paroxysmal Nocturnal Hemoglobinuria. One-third of patients with PNH…”
Get full text

Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management by Terpos, E., Branagan, A.R., García-Sanz, R., Trotman, J., Greenberger, L.M., Stephens, D.M., Morel, P., Kimby, E., Frustaci, A.M., Hatjiharissi, E., San-Miguel, J., Dimopoulos, M.A., Treon, S.P., Leblond, V.

“…Consensus Panel 5 (CP5) of the 11th International Workshop on Waldenstrom's Macroglobulinemia (IWWM-11; held in October 2022) was tasked with reviewing the…”
Get full text

Characterization of familial Waldenstrom's macroglobulinemia by TREON, S. P, HUNTER, Z. R, TOURNILHAC, O, PATTERSON, C. J, MANNING, R, BRANAGAN, A. R, MORTON, C. C, AGGARWAL, A, EWEN, E. P, MASOTA, S, LEE, C, DITZEL SANTOS, D, HATJIHARISSI, E, XU, L, LELEU, X

“…Familial clustering of B-cell disorders among Waldenström's macroglobulinemia (WM) patients has been reported, though the frequency and any differences in…”
Get full text

P16: DARATUMUMAB MONOTHERAPY HAS A FAVORABLE EFFECT ON BONE METABOLISM IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA; RESULTS OF THE PHASE 2 REBUILD STUDY by Terpos, E, Ntanasis‐Stathopoulos, I, Kastritis, E, Hatjiharissi, E, Katodritou, E, Eleutherakis‐Papaiakovou, E, Verrou, E, Gavriatopoulou, M, Leonidakis, A, Delimpasi, S, Malandrakis, P, Kyrtsonis, M‐C, Papaioannou, M, Symeonidis, A, Dimopoulos, MA

Get full text

PB1936: PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND THROMBOSIS: A MULTICENTRIC RETROSPECTIVE STUDY by Chatzileontiadou, S., Loutsidi, N.‐E., Asimakopoulos, I., Chatzikonstantinou, T., Zikos, P., Bouchla, A., Bezirgiannidou, Z., Kouvata, E., Apsemidou, A., Frouzaki, C., Hatjiharissi, E., Chaloudis, P., Sotiropoulos, D., Douka, V., Syrigou, A., Mandala, E., Psyllaki, M., Papadaki, H., Marinakis, T., Viniou, N.‐A., Kokori, S., Vassilopoulos, G., Kotsianidis, I., Pappa, V., Pagoni, M., Lalayanni, C., Anagnostopoulos, A., Baltadakis, I., Delimpassi, S., Angelopoulou, M., Papaioannou, M.

Get full text

Efficacy and safety of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment: results of the phase 2 dare study by E. Terpos, A. Symeonidis, S. Delimpasi, E. Zamagni, E. Katodritou, E. Rivolti, M. Kyrtsonis, D. Fotiou, N. Kanellias, M. Migkou, M. Roussou, M. Gavriatopoulou, E. Hatjiharissi, M. Cavo, M. Dimopoulos

Get full text

Long-term outcome of primary endocrine non-Hodgkin lymphomas: does the site make the difference? by Hatjiharissi, E, Diamantidis, M D, Papaioannou, M, Dimou, T, Chrisoulidou, A, Patakiouta, F, Constantinou, N, Pazaitou-Panayiotou, K

“…Primary lymphomas of endocrine glands are extremely rare. Our study adds more data to the few published series regarding the incidence, clinical…”
Get full text

LONG‐TERM FOLLOW‐UP OF PATIENTS WITH NON‐HODGKIN PRIMARY DIFFUSE LARGE B‐CELL LYMPHOMA OF THE STOMACH: BETTER OUTCOME AFTER IMMUNOCHEMOTHERAPY by Hatjiharissi, E., Diamantidis, M.D., Papadopoulou, A., Chatzileontiadou, S., Gerofotis, A., Pouptsis, A., Karabatzakis, N., Pentidou, K., Patakiouta, F., Constantinou, N., Papaioannou, M.

Get full text

The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma by Hatjiharissi, E., Terpos, E., Papaioannou, M., Hatjileontis, C., Kaloutsi, V., Galaktidou, G., Gerotziafas, G., Christakis, J., Zervas, K.

“…The aim of the study was the evaluation of anti‐angiogenic activity of the combination of intermediate doses of thalidomide and dexamethasone in patients with…”
Get full text

Distinct T Cell Receptor Gene Repertoires and T Cell Subset Distribution in Peripheral Blood and Bone Marrow of Patients with Multiple Myeloma by Gkoliou, Glykeria, Pechlivanis, Nikolaos, Chatzileontiadou, Sofia, Xydopoulou, Chara, Frouzaki, Christina, Karakatsoulis, Georgios, Vlachonikola, Elisavet, Gerousi, Marina, Psomopoulos, Fotis, Papaioannou, Maria, Chlichlia, Katerina, Stamatopoulos, Kostas, Hatjiharissi, Evdoxia, Chatzidimitriou, Anastasia

“…Mounting evidence suggests that the T cell repertoire in multiple myeloma (MM) is actively shaped by antigen selection. However, the molecular underpinnings of…”
Get full text

T Cell Epitope Prediction within the Clonotypic Immunoglobulin Heavy and Light Chains in Patients with Multiple Myeloma by Gkoliou, Glykeria, Pechlivanis, Nikos, Chatzileontiadou, Sofia, Xydopoulou, Chara, Frouzaki, Christina, Karakatsoulis, Georgios, Vlachonikola, Elisavet, Gerousi, Marina, Psomopoulos, Fotis, Papaioannou, Maria, Chlichlia, Katerina, Stamatopoulos, Kostas, Hatjiharissi, Evdoxia, Chatzidimitriou, Anastasia

Get full text

Longitudinal T Cell Immunoprofiling of Patients with Relapsed and/or Refractory Myeloma Who Receive Daratumumab Monotherapy: A Subanalysis of a Phase 2 Study (the REBUILD Study) by Vlachonikola, Elisavet, Vardi, Anna, Kastritis, Eftathios, Hatjiharissi, Evdoxia, Katodritou, Eirini, Siorenta, Alexandra, Sofou, Electra, Kotta, Konstantia, Karipidou, Maria, Gavriatopoulou, Maria, Delimpasi, Sosana, Symeonidis, Argiris, Stamatopoulos, Kostas, Dimopoulos, Meletios A., Terpos, Evangelos, Chatzidimitriou, Anastasia

“…Recent evidence suggests immunomodulatory effects of daratumumab in heavily pre-treated Multiple Myeloma (MM) patients (pts); however, the precise effects…”
Get full text

Differences in the immunoglobulin gene repertoires of IgG versus IgA multiple myeloma allude to distinct immunopathogenetic trajectories by Gkoliou, Glykeria, Agathangelidis, Andreas, Karakatsoulis, Georgos, Lalayanni, Chrysavgi, Papalexandri, Apostolia, Medina, Alejandro, Genuardi, Elisa, Chlichlia, Katerina, Hatjiharissi, Evdoxia, Papaioannou, Maria, Terpos, Evangelos, Jimenez, Cristina, Sakellari, Ioanna, Ferrero, Simone, Ladetto, Marco, Sanz, Ramon Garcia, Belessi, Chrysoula, Stamatopoulos, Kostas

“…The analysis of the immunogenetic background of multiple myeloma (MM) has proven key to understanding disease ontogeny. However, limited information is…”
Get full text

Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy by Kastritis, Efstathios, Kyrtsonis, Marie-Christine, Morel, Pierre, Gavriatopoulou, Maria, Hatjiharissi, Evdoxia, Symeonidis, Argirios S, Vassou, Amalia, Repousis, Panagiotis, Delimpasi, Sossana, Sioni, Anastasia, Michalis, Evrydiki, Michael, Michail, Vervessou, Elina, Voulgarelis, Michael, Tsatalas, Costantinos, Terpos, Evangelos, Dimopoulos, Meletios A

Get full text

THE STAT SIGNALING BIOSIGNATURE OF CD4+ T CELL SUBSETS REFLECT THE IMMUNOGENICITY OF HIGH-RISK MDS AND PREDICT AZACYTIDINE TREATMENT OUTCOME: PF537 by Lamprianidou, E., Kordella, C., Zoulia, E., Papoutselis, M., Bezirgiannidou, Z., Vrachiolias, G., Spanoudakis, E., Vassilakopoulos, T., Galanopoulos, A., Papageorgiou, S., Pappa, V., Vakalopoulou, S., Garipidou, V., Papaioannou, M., Hatjiharissi, E., Diamantopoulos, P., Viniou, N.-A., Kotsianidis, I.

Get full text

PF537 THE STAT SIGNALING BIOSIGNATURE OF CD4+ T CELL SUBSETS REFLECT THE IMMUNOGENICITY OF HIGH‐RISK MDS AND PREDICT AZACYTIDINE TREATMENT OUTCOME by Lamprianidou, E., Kordella, C., Zoulia, E., Papoutselis, M., Bezirgiannidou, Z., Vrachiolias, G., Spanoudakis, E., Vassilakopoulos, T., Galanopoulos, A., Papageorgiou, S., Pappa, V., Vakalopoulou, S., Garipidou, V., Papaioannou, M., Hatjiharissi, E., Diamantopoulos, P., Viniou, N.‐A., Kotsianidis, I.

“…Background: Azacytidine (AZA) is the mainstream treatment in high‐risk Myelodysplastic Syndromes (MDS), but the exact mechanism of action and resistance is…”
Get full text

Tartrate‐resistant acid phosphatase isoform 5b: A novel serum marker for monitoring bone disease in multiple myeloma by Terpos, Evangelos, de la Fuente, Josu, Szydlo, Richard, Hatjiharissi, Evdoxia, Viniou, Nora, Meletis, John, Yataganas, Xenophon, Goldman, John M, Rahemtulla, Amin

“…Tartrate‐resistant acid phosphatase isoform‐5b (TRACP‐5b), a new marker reflecting osteoclast activity, and osteoprotegerin (OPG) were measured in 121 patients…”
Get full text

TNF-a, retinoid acid and STAT4 pathways are differentially regulated by the HDAC inhibitors, SAHA, TSA and Sirtinol in Waldenstrom's Macroglobulinemia by Hunter, Z., Sun, J., Tseng, H., Hatjiharissi, E., Maghsoudi, K., Xu, L., Manning, R., Munshi, N., Anderson, K., Treon, S.

“…Abstract only e14582 Background: HDAC inhibitors (HDAC-I) have emerged as a promising class of therapeutics for the treatment of lymphoplasmacytic…”
Get full text

IgG and IgA hypogammaglobulinemia is pervasive in Waldenstrom's macroglobulinemia (WM) and persists regardless of response or type of therapeutic intervention by Hunter, Z. R., O'Connor, K., Soumerai, J., Branagan, A., Leleu, X., Hatjiharissi, E., Treon, S.

“…Abstract only 8042 Background: IgG and IgA hypogammaglobulinemia (HG) is a commonly observed in patients with WM and has often been attributed to the extensive…”
Get full text

A SCID-hu in vivo model of human Waldenström macroglobulinemia by Tassone, Pierfrancesco, Neri, Paola, Kutok, Jeffery L., Tournilhac, Olivier, Santos, Daniel Ditzel, Hatjiharissi, Evdoxia, Munshi, Vidit, Venuta, Salvatore, Anderson, Kenneth C., Treon, Steven P., Munshi, Nikhil C.

“…The preclinical evaluation of investigational agents for Waldenström macroglobulinemia (WM) has been limited by the lack of in vivo models that enable the use…”
Get full text